News
News Home
Quick Bites
Exploradio
News Archive
News Channel
Special Features
NPR
nowplaying
On AirNewsClassical
Loading...
  
School Closings
WKSU Support
Funding for WKSU is made possible in part through support from the following businesses and organizations.

Hospice of the Western Reserve

Area Agency on Aging 10B, Inc.


For more information on how your company or organization can support WKSU, download the WKSU Media Kit.

(WKSU Media Kit PDF icon )


Donate Your Vehicle to WKSU

Programs Schedule Make A Pledge Member BenefitsFAQ/HelpContact Us
Health and Medicine


Change in FDA policy fast tracks testing of Alzheimer's drug
But other scientists are unable to reproduce dramatic improvements shown in preliminary tests in Cleveland
by WKSU's JEFF ST. CLAIR


Reporter / Host
Jeff St. Clair
 
Dr. Gary Landeth (right) hopes to prove that Bexarotene can treat Alzheimer’s disease through phase 1 clinical trials. He and then graduate student Paige Cramer started a company called Rexceptor to develop the drug for clinical use.
Courtesy of Jeff St.Clair
Download (WKSU Only)
In The Region:

A promising new treatment for Alzheimer’s disease developed in Cleveland has run into some roadblocks, but backers of a repurposed drug are moving forward with clinical trials.

LISTEN: ST.CLAIR ON ALZHEIMER'S DRUG

Other options:
Windows Media / MP3 Download (1:04)


The drug Bexarotene was originally used to treat skin cancer. But Gary Landreth, a neuroscientist at Case Western Reserve University, showed last year that mice bred to have Alzheimer’s disease dramatically improved when given the drug. Now Landreth is ready to test it on people.

He says a recent change in FDA policy allows the drug to be tested on healthy people to determine whether it reduces soluble amyloid beta proteins that are believed to lead to Alzheimer’s.

“The FDA has recognized we now need to treat people who are at risk of Alzheimer’s disease but are cognitively normal, and that changes everything,” Landreth says.

The scientific community, however, is not convinced the drug actually works. Last week, the journal "Science" published independent studies that failed to reproduce Landreth’s dramatic results. However, he says he is still holding out hope his original findings in mice will be validated.

“Proving this mechanism in humans is essential to any subsequent development of the drug,” Landreth says.

Landreth says he could know by the end of the year whether Bexarotene will move on to further testing or join the dozens of other would-be Alzheimer treatments littering the path to a cure.

Listener Comments:

Does anyone have any idea as to what dosage they will be testing?


Posted by: DICKY_DOOO on May 28, 2013 4:05AM
Add Your Comment
Name:

Location:

E-mail: (not published, only used to contact you about your comment)


Comments:




 
Page Options

Print this page

E-Mail this page / Send mp3

Share on Facebook




Stories with Recent Comments

Lordstown GM plant plans to install 8,500 solar panels
How much will this solar array cost? How is it being funded, and who is really paying for it? How much real useful electricity will it actually produce in MEh p...

Local Ebola concerns cause officials to pay more attention to West Africa
I have a better idea, let's secure our borders and spend those billions of dollars on our own first.

HUD and Cuyahoga Land Bank extend a housing deal for another year
Need to sale lot, and would like to know how to contact someone to see if they may be interested in the property that sat between two lots. If you can give me...

Akron Beacon Journal details abuse claims against televangelist Angley
In the early 90's I went forth for pray. And the man was anointed by the hand of God. Just a fact I will never forget

Lawmaker questions why a million voters didn't get absentee applications
He's a damn lie! I vote n all elections. I missed 1. Haven't gotten my absentee ballot and their making it hard to get one.

Thirsty Dog Brewery warns it might have to leave Akron
Why is it the city's responsibility to find this guy a location? There are a hundred realestate companies that could help him.

Kent State sends home three after contact with second Ebola-stricken nurse
Why weren't all health workers who were around Duncan quaranteened for 21 days and tested for Ebola? That's a no-brainer. Why was Vinson allowed to travel right...

New book says Willoughby Coal is haunted...and that's good for business
Would love to see a series of books that would just thrill me. I cannot wait to visit some of the locations. And revisit some of the locations I have already vi...

Cleveland Indians to continue with 'dynamic pricing'
pricing is too high for a family as well as people like me who are on a fixed income. Bleacher seats are cheaper but concessions are rediculous.

Kasich talks about faith, drugs and education -- but never FitzGerald
The idea that you can learn more by talking to a 90 year old person than from a history book is just another example of how the GOP hates education and knowledg...

Copyright © 2014 WKSU Public Radio, All Rights Reserved.

 
In Partnership With:

NPR PRI Kent State University

listen in windows media format listen in realplayer format Car Talk Hosts: Tom & Ray Magliozzi Fresh Air Host: Terry Gross A Service of Kent State University 89.7 WKSU | NPR.Classical.Other smart stuff. NPR Senior Correspondent: Noah Adams Living on Earth Host: Steve Curwood 89.7 WKSU | NPR.Classical.Other smart stuff. A Service of Kent State University